學門類別
最新個案
- Leadership Imperatives in an AI World
- Vodafone Idea Merger - Unpacking IS Integration Strategies
- V21 Landmarks Pvt. Ltd: Scaling Newer Heights in Real Estate Entrepreneurship
- Snapchat’s Dilemma: Growth or Financial Sustainability
- Did I Just Cross the Line and Harass a Colleague?
- Predicting the Future Impacts of AI: McLuhan’s Tetrad Framework
- Porsche Drive (A) and (B): Student Spreadsheet
- Porsche Drive (B): Vehicle Subscription Strategy
- TNT Assignment: Financial Ratio Code Cracker
- Winsol: An Opportunity For Solar Expansion
Medicare and Drug-eluting Stents
內容大綱
The U.S. Food and Drug Administration has recently approved a drug-coated stent for use in angioplasty procedures. The stent is expected to reduce the rate of repeat procedures due to restenosis, and to postpone the need for more invasive surgery such as coronary bypass. However, the drug-coated stent costs three times as much as an uncoated stent, which will increase the cost of the medical procedure. Public demand for the stent is overwhelming, because of the higher cost and huge demand, cost of medical care could increase dramatically. Students need to think about the trade-off between quality improvements and higher costs of medical treatment by looking at the impact on several stakeholders: patients, hospitals and insurers.